Evelo: Evelo Biosciences: EDP2939-101 Study Fails To Meet Endpoint; To Explore Strategic Alternatives

(RTTNews) - Evelo Biosciences, Inc. (EVLO) announced top-line results from Phase 2 clinical study with EDP2939 in moderate psoriasis. The primary endpoint, the difference in the proportion of patients who achieved an outcome of a 50% improvement from baseline in Psoriasis Area an